SAN DIEGO, CA, November 24, 2013 /24-7PressRelease/ -- Markus Haeberlein, Senior Vice President and Head of Research at Proteostasis Therapeutics will give a presentation titled "The Development of Usp14 Inhibition as Disease-Modification, Therapeutics for Protein Aggregation Diseases," at the 4th Ubiquitin Research and Drug Discovery Conference to be held in San Diego, CA on February 20-21, 2014 by GTC. Dr. Haeberlein's talk includes the effects on aggregation-prone proteins from a knockdown of Usp14, and the effect of pharmacological inhibition of Usp14 on aggregation-prone proteins.

Dr. Haeberlein joined AstraZeneca CNS & Pain Research in Sweden in 1997 and spent the next 15 years in positions of increasing responsibility, most recently as AstraZeneca Global Chemistry Network leader and Head of Medicinal Chemistry. Dr. Haeberlein has an extensive knowledge in neuroscience drug discovery and contributed to a large number of neurology and pain drug candidates as well as novel PET ligands.

For more information, please visit http://www.gtcbio.com/conference/ubiquitin/agenda

GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic institutions, government organizations and the financial community.

GTC (Global Technology Community), LLC, is a privately held company founded in 2002.